Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVNNASDAQ:KODNASDAQ:MLYSNASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$20.68-3.9%$19.32$13.30▼$30.03$1.01B0.79290,804 shs1.44 million shsKODKodiak Sciences$3.70-2.1%$3.85$1.92▼$11.60$195.23M2.27344,849 shs275,486 shsMLYSMineralys Therapeutics$13.71-2.1%$14.88$8.24▼$18.38$893.55M-0.17539,476 shs2.23 million shsPHVSPharvaris$17.00-5.0%$16.79$11.51▼$25.50$888.93M-2.8671,580 shs33,521 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics-3.90%-2.91%+28.69%-1.85%-2.36%KODKodiak Sciences-2.12%+2.21%+5.71%+27.15%+61.57%MLYSMineralys Therapeutics-2.07%+1.71%-13.45%-6.48%+23.62%PHVSPharvaris-5.03%-5.50%+9.96%+7.59%-6.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELVNEnliven Therapeutics2.2191 of 5 stars3.50.00.00.02.54.20.0KODKodiak Sciences4.3778 of 5 stars3.04.00.04.63.03.30.0MLYSMineralys Therapeutics2.1094 of 5 stars3.41.00.00.01.54.20.0PHVSPharvaris1.4268 of 5 stars3.51.00.00.01.90.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 3.00Buy$39.6091.49% UpsideKODKodiak Sciences 2.00Hold$9.00143.24% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$32.25135.23% UpsidePHVSPharvaris 3.00Buy$36.20112.94% UpsideCurrent Analyst Ratings BreakdownLatest KOD, MLYS, ELVN, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.006/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.006/11/2025PHVSPharvarisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$32.006/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.006/5/2025PHVSPharvarisWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/14/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/APHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)PHVSPharvaris-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)Latest KOD, MLYS, ELVN, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A21.0721.06KODKodiak SciencesN/A4.624.62MLYSMineralys TherapeuticsN/A26.4826.48PHVSPharvarisN/A11.1011.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%KODKodiak Sciences89.06%MLYSMineralys Therapeutics84.46%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics25.90%KODKodiak Sciences45.90%MLYSMineralys Therapeutics25.56%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableKODKodiak Sciences9052.76 million28.55 millionOptionableMLYSMineralys Therapeutics2865.18 million48.52 millionOptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableKOD, MLYS, ELVN, and PHVS HeadlinesRecent News About These CompaniesPharvaris (NASDAQ:PHVS) Trading Down 4.9% - What's Next?June 27 at 2:03 PM | marketbeat.comPharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National SummitJune 27 at 6:50 AM | globenewswire.comPharvaris N.V. (9EN.F) stock price, news, quote & history - Yahoo FinanceJune 26 at 8:28 AM | sg.finance.yahoo.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and Pharvaris (PHVS)June 24, 2025 | theglobeandmail.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...June 16, 2025 | gurufocus.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...June 16, 2025 | gurufocus.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI CongressJune 16, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Shares Gap Up - What's Next?June 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Given Average Rating of "Buy" by BrokeragesJune 11, 2025 | marketbeat.comCantor Fitzgerald Predicts Pharvaris FY2026 EarningsJune 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Now Covered by Analysts at GuggenheimJune 11, 2025 | marketbeat.comBank of America Corp DE Increases Stake in Pharvaris (NASDAQ:PHVS)June 11, 2025 | marketbeat.comPharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 TrialsJune 10, 2025 | tipranks.comPharvaris Announces Annual Meeting of ShareholdersJune 10, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,838 Shares of Pharvaris (NASDAQ:PHVS)June 10, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for Pharvaris Q2 Earnings?June 9, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Pharvaris (NASDAQ:PHVS)June 5, 2025 | marketbeat.comPharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 TrialsJune 5, 2025 | tipranks.comPharvaris reports promising results for deucrictibant in HAEJune 3, 2025 | investing.comPharvaris reports promising results for deucrictibant in HAEJune 3, 2025 | investing.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?June 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, MLYS, ELVN, and PHVS Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$20.68 -0.84 (-3.90%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$20.68 0.00 (0.00%) As of 06/27/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Kodiak Sciences NASDAQ:KOD$3.70 -0.08 (-2.12%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.85 +0.15 (+4.03%) As of 06/27/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Mineralys Therapeutics NASDAQ:MLYS$13.71 -0.29 (-2.07%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$13.72 +0.01 (+0.07%) As of 06/27/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Pharvaris NASDAQ:PHVS$17.00 -0.90 (-5.03%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$16.90 -0.10 (-0.59%) As of 06/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
